Search
for

    Community Join

    5 / 36 results

      community Breezula - who tried CB0301/Clascoterone from gray marked/pharmas ?

       1 upvotes 7 months ago
      The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

      community What do we currently know about clascoterone?

       7 upvotes 8 months ago
      Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

      community Why are people so negative regarding Clascoterone (Breezula)?

       20 upvotes 4 months ago
      Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.

      community Breezula is a good alternative

       8 upvotes 5 months ago
      Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

      research Clascoterone: a new topical antiandrogen agent.

      February 2025 in “Prospects in Pharmaceutical Sciences”
      This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

      research Expanding the therapeutic versatility of clacosterone

      October 2023 in “Journal of the American Academy of Dermatology”
      This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

      research Clascoterone: First Approval

      27 citations , October 2020 in “Drugs”
      This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

      research Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review

      August 2026 in “Pharmaceuticals”
      This review summarizes existing evidence about clascoterone cream, which significantly reduces acne lesions with a favorable safety profile, but reports no new clinical results and suggests further research for other potential applications.